Makers Laboratories Limited reported a standalone net loss of ₹1.72 crore for the financial year ended March 31, 2026, reversing its net profit of ₹4.64 crore in the previous year. The company’s total income declined to ₹50.94 crore in FY26 from ₹53.87 crore in the preceding financial year.

The standalone operations resulted in a profit before interest, depreciation, and taxation of ₹1.32 crore, significantly lower than the ₹8.71 crore recorded in FY25. After accounting for depreciation, finance costs, and tax expenses, the company posted a net loss for the period. The financial figures for the current year are not strictly comparable to the previous year, as the prior year’s operations included other income and a profit of ₹18.50 crore from the sale of office premises in Mumbai.

The company attributed the decline in financial performance to lower growth in its generic formulations business due to reduced prevalence of acute diseases and decreased demand for liquid injectables. Additionally, depreciation charges, finance costs, and other overheads related to its new ophthalmic eye drops manufacturing facility in GIDC, Naroda, Ahmedabad, which was commercialised in FY21, impacted profitability. This unit has started manufacturing eye drops for the Eurasia market, with more product dossiers under registration in Rest of World (ROW) markets.

On a consolidated basis, sales and other income rose to ₹142.30 crore in FY26 from ₹132.64 crore in FY25, representing a growth of 7%. However, consolidated net profit after non-controlling interest fell to ₹2.35 crore from ₹7.49 crore in the previous year. The company’s subsidiary, Resonance Specialties Ltd., in which it holds a 45.48% stake, reported a total income of ₹91.99 crore and a net profit of ₹10.40 crore for the year.

Financial Highlights

The Board of Directors has recommended that no dividend be declared for the financial year ended March 31, 2026, in view of the losses incurred in the standalone financials. The company’s research and development expenditure for the year stood at ₹21.27 lacs, constituting 0.42% of the turnover.

Makers Laboratories Limited has scheduled its 41st Annual General Meeting (AGM) for August 7, 2026, to be conducted through video conferencing. The meeting will comply with the provisions of the Companies Act, 2023, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Members attending via video conferencing will be reckoned for the purpose of quorum under Section 103 of the Act.

Notice and Document Availability

The Notice of the AGM and the Financial Statements for the financial year 2025-26, along with the Reports of the Board of Directors and Auditors, will be sent exclusively by email to members whose email addresses are registered with the company or its Registrar and Share Transfer Agent. These documents will also be accessible on the company's website at www.makerslabs.com , the BSE website, and the National Securities Depository Services Ltd. (NSDL) portal.

E-voting and Participation

Shareholders can exercise their right to vote on agenda items through electronic means provided by NSDL. Additionally, the facility of voting through the e-voting system will be available during the AGM. Detailed procedures for remote e-voting and voting during the meeting will be emailed to members shortly.

Registration Details

Members holding shares in physical mode must send an email to the company or its RTA with their registered folio number, email address, self-attested PAN card, address proof, contact number, and bank account particulars to register or update their details. Those holding shares in demat mode should contact their Depository Participant to register their email and bank account details.